BeiGene, Ltd. (ONC)vsTango Therapeutics Inc (TNGX)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
TNGX
Tango Therapeutics Inc
$20.88
+7.19%
HEALTHCARE · Cap: $2.98B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 8465% more annual revenue ($5.34B vs $62.38M). ONC leads profitability with a 5.4% profit margin vs -162.9%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
TNGX
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for TNGX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Trading at 8.2x book value
0.0% earnings growth
ROE of -37.2% — below average capital efficiency
Revenue declined 100.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : TNGX
TNGX has a balanced fundamental profile.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : TNGX
The primary concerns for TNGX are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while TNGX is a turnaround play — different risk/reward profiles.
TNGX carries more volatility with a beta of 1.81 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 20/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Tango Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tango Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of targeted therapies aimed at addressing significant unmet needs in cancer treatment, particularly through the innovative concept of synthetic lethality. With a diverse pipeline of promising drug candidates, Tango is well-positioned to lead advancements in precision oncology, focusing on collaborative partnerships with leading research institutions to enhance its scientific capabilities. The company's strategic vision is to transform cancer care and improve patient outcomes, positioning it as a key player in the evolution of treatment paradigms in oncology.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?